Table 11. Estimated additional costs to launch 18“missing” products.
| Disease | Archetype | Additional number of candidates
needed at preclinical phase |
Additional investment needed to achieve
one expected launch ($, millions) |
|---|---|---|---|
| HIV/AIDS | Unprecedented
vaccine |
125 | 2844.4 |
| TB | Unprecedented
vaccine |
169 | 3845.6 |
| Malaria | Unprecedented
vaccine |
171 | 3891.1 |
| Hepatitis C | Simple vaccine | 6 | 222.2 |
| Hepatitis C | Complex vaccine | 30 | 915.6 |
| Multiple diarrheal
diseases |
Simple vaccine | 11 | 406.6 |
| Multiple diarrheal
diseases |
Complex vaccine | 35 | 1057.4 |
| TB | Complex NCE | 27 | 495.0 |
| 12 NTDs * | Simple NCE | 101 | 1851.6 |
| 12 NTDs * | Complex NCE | 478 | 8762.9 |
*These diseases are Buruli ulcer, Chagas disease, dengue, hookworm, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, schistosomiasis, trachoma, sleeping sickness and trichuriasis